Provectus Biopharmaceuticals Inc (PVCT) USD0.001
$0.0005
(0.94%)
- Add to watchlist
- This stock can be held in a
$0.0005
(0.94%)
Deal for just £11.95 per trade in a
Fund and Share Account
$0.0005
(0.94%)
Business summary
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing immunotherapy medicines for different diseases. Its immunotherapy medicines are based on a family of small molecules called halogenated xanthenes (HXs). Its lead HX molecule is named rose bengal disodium (RBD). Its product pipeline includes PV-10 and PH-10. PV-10 is an investigational cancer immunotherapy administered by intralesional (IL) injection and an injectable formulation of cGMP RBD, is undergoing clinical study for adult solid tumor cancers, such as melanoma and gastrointestinal (GI) tumors. PH-10 is an investigational immuno-dermatology agent administered as a topical gel and formulation of cGMP RBD, is undergoing monotherapy clinical study and preclinical study of combination therapy with approved drugs for inflammatory dermatoses. It is also developing clinical programs for the treatment of SARS-CoV-2, Gram-positive bacteria, Infectious Keratosis and others.
Contact details
Important dates
General stock information
- Short code:
- PVCT
- ISIN:
- US74373P1084
- Market cap:
- $22.52 million
- Shares in issue:
- 419.45 million
- Sector:
- Pharmaceuticals
- Exchange:
- Off Exchange
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.